NY-MEDICREA
20.9.2018 15:09:05 CEST | Business Wire | Press release
The Medicrea Group (Euronext Growth Paris: FR0004178572 – ALMED, PEA-PME eligible, and OTCQX: MNRTY and MNRTF), pioneering the transformation of spinal surgeries through Artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI (Adaptive Spine Intelligence) technology, announced today that the Company is attending the Eurospine 2018 meeting taking place in Barcelona, Spain, from September 19th to 21st , where UNiD™ LAB biomedical engineers will showcase the most recent developments of the Company’s UNiD™ ASI technology.
Denys Sournac, President and Chief Executive Officer, stated, “At Eurospine 2018, our team of biomedical engineers will show attending spine surgeons how the UNiD™ASI technology answers the gap left by traditional implant manufacturers through a demonstration of the UNiD™ HUB, a software platform that fully integrates surgical planning through machine learning to generate personalized implants that are adapted to each individual patient and at the same time to each individual surgeon technique.”
Five years after its initial launch in September 2013, over 2,800 patients have benefited from UNiD™ ASI 100% proprietary pre-operative planning technologies and services associated with patient-specific spinal realignment rods, with a strong acceleration in adoption rate in 2018 (+60% cases in year-to-date 2018) especially in the USA.
Since its inception, the technology supported surgeons specializing in adult indications with planning services and patient-specific implants focused on restoring sagittal alignment. More recently, surgeons have found the technology to be fully applicable to the pediatric population as well. As such, surgeons have increasingly published on the application of UNiD™ ASI in pediatrics and have begun to demonstrate the importance of respecting sagittal parameters in the pediatric population.
Jean-Luc Clément, M.D. of Fondation Lenval (Nice, FRANCE) and UNiD™ASI user recently published the Article titled “Surgical Increase of Thoracic Kyphosis Increases Unfused Lumbar Lordosis in Selective Fusion for Thoracic Adolescent Idiopathic Scoliosis” . In this article, Jean-Luc Clément emphasizes “...the importance of restoring adequate kyphosis and respecting the links between sagittal parameters (thoracic kyphosis, lumbar lordosis and pelvic incidence) specifically in adolescent surgery. A task which is close to impossible for a surgeon without the appropriate tools that are now provided by Medicrea through UNID™ ASI Platform. Data analytics and predictive modeling are topics that surgeons and healthcare professionals recognize will shape the future of care and the way we view spine surgery.”
The recent publication by Jean-Luc Clément, M.D. et al. hypothesizes that correction of hypokyphosis in AIS increases lumbar lordosis, especially its proximal part by reciprocal changes. The study involves 111 patients selectively instrumented using the ST2R technique on the thoracic region with 2 years of follow-up. The author demonstrates and evaluates that non-instrumented lumbar lordosis was directly increased and proportionally impacted by the thoracic kyphosis correction.
Jean-Luc Clément also stated, “These results are supporting the use of the UNiD™ ASI platform to obtain the expected patient-specific thoracic kyphosis to adapt lumbar lordosis to the patient’s specific pelvic incidence.”
Medicrea’s proprietary UNiD™ ASI technology and services integrates numerous proprietary predictive models, one of which takes into consideration the post-operative compensatory mechanisms occurring on the non-instrumented portion of the spine both above and below the construct. Through the UNiD™ HUB, the algorithms use large amounts of data to generate intelligent surgical planning through machine learning while simultaneously allowing the surgeon to perform detailed, custom analysis of the cases. Medicrea uses proprietary data science to drive improved outcomes and economic efficiencies in spine surgery.
Meeting attendees are invited to learn more about Medicrea at Booth 33B.
About Medicrea (www.medicrea.com)
Through the lens of predictive medicine, Medicrea leverages its proprietary software analysis tools with big data and machine learning technologies supported by an expansive collection of clinical and scientific data. The Company is well-placed to streamline the efficiency of spinal care, reduce procedural complications and limit time spent in the operating room.
Operating in a $10 billion marketplace, Medicrea is a Small and Medium sized Enterprise (SME) with 200 employees worldwide, which includes 50 who are based in the U.S. The Company has an ultra-modern manufacturing facility in Lyon, France housing the development and production of 3D- printed titanium patient-specific implants.
For further information, please visit: Medicrea.com.
Connect with Medicrea
FACEBOOK
| INSTAGRAM
| TWITTER
| WEBSITE
| YOUTUBE
Medicrea
is listed on
EURONEXT Growth Paris
ISIN:
FR 0004178572
Ticker:
ALMED
LEI:
969500BR1CPTYMTJBA37
Medicrea is traded on
OTCQX Best Market
Tickers:
MNRTY & MRNTF
View source version on businesswire.com: https://www.businesswire.com/news/home/20180920005476/en/
Contact:
Medicrea Denys Sournac Founder, Chairman and CEO dsournac@medicrea.com or Fabrice Kilfiger, +33 (0)4 72 01 87 87 Chief Financial Officer fkilfiger@medicrea.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release
Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
